BLI 1009

Drug Profile

BLI 1009

Alternative Names: BLI-1009

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator BioLite Inc
  • Class Anti-ischaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 17 Feb 2016 No development reported - Phase-III for Stroke in Taiwan (unspecified route)
  • 30 Jan 2013 Phase-III clinical trials in Ischaemia in Taiwan (unspecified route)
  • 30 Jan 2013 Phase-III clinical trials in Stroke in Taiwan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top